By Nigam Arora Diversification Banks stocks provide good diversification for portfolios heavily weighted in AI. Positive Tailwinds The following are providing positive tailwinds for bank stocks: Robust capital markets High net interest income Strong loan growth Deregulation Earnings JPM, WFC, C, and GS kicked off earnings season today. All banks reported
By Nigam Arora Nigam Arora returns to the Schwab Network and weighs in on job cuts in banks, saying AI will be a factor to increase productivity and could be the “fly in the ointment” for that segment of the labor market. Watch the interview for what investors need to know. To
By Nigam Arora To gain an edge, this is what you need to know today. Rate Cut Hopes Win Out Please click here for a chart of S&P 500 ETF (SPY) which represents the benchmark stock market index S&P 500 (SPX). Note the following: The chart shows the stock market drop
By Nigam Arora To gain an edge, this is what you need to know today. TACO Traders Meet CAHN Please click here for a chart of JPMorgan Chase stock (JPM). Note the following: The Morning Capsule is about the big picture, not an individual stock. The chart of JPM stock is
By Nigam Arora To gain an edge, this is what you need to know today. Euphoric TACO Traders Please click here for a chart of S&P 500 ETF (SPY) which represents the benchmark stock market index S&P 500 (SPX). Note the following: The chart shows the big drop in the stock
By Nigam Arora Editors Notes: Hours before Trump’s new tariffs news hit and S&P 500 dropped 2.7% as well as NASDAQ dropped 3.4%, The Arora Report warned: “History teaches a trigger often comes from nowhere” In the morning before the big drop in the stock market, The Arora Report issued
By Nigam Arora To gain an edge, this is what you need to know today. Correction Trigger Please click here for a chart of S&P 500 ETF (SPY) which represents the benchmark stock market index S&P 500 (SPX). Note the following: The chart shows the stock market is way above the
By Nigam Arora NVO, the maker of weight loss drug Wegovy, is buying AKRO. The deal is for $60 per share. The deal consists of $54 per share in cash to be paid on closing and $6 per share in cash upon U.S. regulatory approval of efruxifermin drug cirrhosis. What To
By Nigam Arora Here are the key points: NVDA is a prime target for buying by year end chasing money managers. This is a positive. NVDA appears to be engaging in circular financing with OpenAI and CRWV. This morning we shared with you the OpenAI deal with AMD. This is a
By Nigam Arora Nigam Arora returns to the Schwab Network and offers perspectives on a wide array of topics. In this latest TV appearance, Nigam Arora explains why AMD’s move isn’t bad for NVDA, how Japan’s trade surge signals strength, and what disciplined investors should do with gold. Watch the interview